Literature DB >> 8253870

Activation of the 92 kDa type IV collagenase by tissue kallikrein.

S Desrivières1, H Lu, N Peyri, C Soria, Y Legrand, S Ménashi.   

Abstract

Type IV collagenases are secreted as latent 92 and 72 kDa proenzymes which are then activated extracellularly. The mechanisms by which they are activated in vivo are not clear. We have studied the activation of porcine endothelial cell type IV collagenases by tissue and plasma kallikrein, and found that tissue kallikrein was a very efficient activator of the 92 kDa type IV collagenase. Enzyme cleavage was observed at concentrations of tissue kallikrein as low as 0.1 microgram/ml. Plasma kallikrein had no effect. By comparison, plasmin, which has been proposed to be the physiological activator of interstitial collagenase and stromelysin, and elastase were much less effective, and high concentrations (plasmin at 100-200 micrograms/ml and elastase at 20 micrograms/ml) were required to cause only a limited cleavage which was not associated with an increase in activity, as observed by the gelatin-gel lysis assay. In addition tissue kallikrein was found by immunohistochemistry to be present in the extracellular matrix of the intima of porcine aortic vessel wall. These findings suggest that tissue kallikrein can be a potential activator of the 92 kDa type IV collagenase in vivo.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8253870     DOI: 10.1002/jcp.1041570319

Source DB:  PubMed          Journal:  J Cell Physiol        ISSN: 0021-9541            Impact factor:   6.384


  23 in total

1.  Leukocytic cell sources of airway tissue kallikrein.

Authors:  Isabel T Lauredo; Rosanna M Forteza; Yelena Botvinnikova; William M Abraham
Journal:  Am J Physiol Lung Cell Mol Physiol       Date:  2003-12-05       Impact factor: 5.464

2.  Expression of kallikrein, bradykinin b2 receptor, and endothelial nitric oxide synthase in placenta in normal gestation, preeclampsia, and placenta accreta.

Authors:  Jenny Corthorn; Alfredo A Germain; Cecilia Chacón; Sergio Rey; Gloria X Soto; Carlos D Figueroa; Werner Müller-Esterl; Ignacio Duarte; Gloria Valdés
Journal:  Endocrine       Date:  2006-06       Impact factor: 3.633

Review 3.  New insights into the functional mechanisms and clinical applications of the kallikrein-related peptidase family.

Authors:  Nashmil Emami; Eleftherios P Diamandis
Journal:  Mol Oncol       Date:  2007-09-15       Impact factor: 6.603

4.  Dual targets for mouse mast cell protease-4 in mediating tissue damage in experimental bullous pemphigoid.

Authors:  Lan Lin; Eric Bankaitis; Lisa Heimbach; Ning Li; Magnus Abrink; Gunnar Pejler; Lijia An; Luis A Diaz; Zena Werb; Zhi Liu
Journal:  J Biol Chem       Date:  2011-08-31       Impact factor: 5.157

5.  Control of type IV collagenase activity by components of the urokinase-plasmin system: a regulatory mechanism with cell-bound reactants.

Authors:  R Mazzieri; L Masiero; L Zanetta; S Monea; M Onisto; S Garbisa; P Mignatti
Journal:  EMBO J       Date:  1997-05-01       Impact factor: 11.598

6.  Requirement for matrix metalloproteinase-9 (gelatinase B) expression in metastasis by murine prostate carcinoma.

Authors:  G Sehgal; J Hua; E J Bernhard; I Sehgal; T C Thompson; R J Muschel
Journal:  Am J Pathol       Date:  1998-02       Impact factor: 4.307

7.  A synthetic tissue kallikrein inhibitor suppresses cancer cell invasiveness.

Authors:  W C Wolf; D M Evans; L Chao; J Chao
Journal:  Am J Pathol       Date:  2001-11       Impact factor: 4.307

8.  Tissue kallikrein in human placenta in early and late gestation.

Authors:  G Valdés; C Chacón; J Corthorn; C D Figueroa; A M Germain
Journal:  Endocrine       Date:  2001-03       Impact factor: 3.633

9.  Synergy between a plasminogen cascade and MMP-9 in autoimmune disease.

Authors:  Zhi Liu; Ning Li; Luis A Diaz; Michael Shipley; Robert M Senior; Zena Werb
Journal:  J Clin Invest       Date:  2005-04       Impact factor: 14.808

10.  Pericellular regulation of prostate cancer expressed kallikrein-related peptidases and matrix metalloproteinases by cell surface serine proteases.

Authors:  Janet C Reid; Admire Matsika; Claire M Davies; Yaowu He; Amy Broomfield; Nigel C Bennett; Viktor Magdolen; Bhuvana Srinivasan; Judith A Clements; John D Hooper
Journal:  Am J Cancer Res       Date:  2017-11-01       Impact factor: 6.166

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.